[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338147-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338147-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analysis-of-10478-cancer-genomes-identifies-candidate-driver-genes-and-opportunities-for-precision-oncology","Analysis of 10,478 Cancer Genomes Identifies Candidate Driver Genes and Opportunities for Precision Oncology","","Tumor genomic profiling supports precision oncology by linking somatic driver mutations to treatment selection. Using whole-genome sequencing from 10,478 patients across 35 cancer types in the UK 100,000 Genomes Project, the study identifies 330 candidate driver genes, including 74 not previously reported in cancer. Approximately 55% of patients show at least one clinically relevant mutation that may predict drug sensitivity or resistance and clinical trial eligibility. Computational chemogenomic analysis further highlights additional compound targets for future trials, assessing impact on real-world precision oncology.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analysis-of-10478-cancer-genomes-identifies-candidate-driver-genes-and-opportunities-for-precision-oncology/338147/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analysis-of-10478-cancer-genomes-identifies-candidate-driver-genes-and-opportunities-for-precision-oncology/338147.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What dataset and sequencing approach were used in the study?","Question",{"text":63,"@type":64},"The analysis used whole-genome sequencing of 10,478 tumor-normal genomes from patients spanning 35 cancer types recruited to the UK 100,000 Genomes Project.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many candidate driver genes were identified, and were any newly discovered?",{"text":68,"@type":64},"The study identified 330 candidate driver genes, including 74 that were not previously known to be associated with any cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the study connect genomic findings to precision oncology?",{"text":72,"@type":64},"It estimates that about 55% of patients harbor clinically relevant mutations that predict sensitivity or resistance to certain treatments or eligibility for clinical trials, and it uses chemogenomic analysis to propose additional druggable targets.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338147,1790906945,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","nature genetics  \nArticle [https://doi.org/10.1038/s41588-024-01785-9](https://doi.org/10.1038/s41588-024-01785-9)  \nAnalysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology  \nReceived: 25 September 2023  \nAccepted: 1 May 2024  \n\n| Published online: 18 June 2024 |\n| --- |\n|  Check for updates |\n\nBen Kinnersley  1,2,11, Amit Sud  1,3,4,5,6,11, Andrew Everall1,11, Alex J. Cornish1, Daniel Chubb1, Richard Culliford1, Andreas J. Gruber  7, Adrian Lärkeryd8, Costas Mitsopoulos9, David Wedge  10 & Richard Houlston  1   \nTumor genomic profiling is increasingly seenasa prerequisite to guide the treatment of patients with cancer. To explore the value of whole-genome sequencing (WGS) in broadening the scope of cancers potentially amenable toa precision therapy, we analysed whole-genome sequencing data on 10,478 patients spanning 35 cancer types recruited to the UK 100,000 Genomes Project. We identified 330 candidate driver genes, including 74 that arenewto any cancer. We estimate that approximately 55% of patients studied harbor at least one clinically relevant mutation, predicting either sensitivity or resistance to certain treatments or clinical trial eligibility. By performing computational chemogenomic analysis of cancer mutations we identify additional targets for compounds that represent attractive candidates for future clinical trials. This study represents oneof the most comprehensive efforts thus far to identify cancer driver genes in the real world setting and assess their impact on informing precision oncology.  \nPrecision oncology aims to tailor therapy to the unique biology of the patient’s cancer, thereby optimizing treatment efficacy and minimizing toxicity1,2. Underpinning precision oncology is the concept of somatic driver mutations asthe foundation of cancer biology3,4.  \nThe expansion in the number of therapeutically actionable genes has exposed the limitations of single-analyte genomic assaysin cancer5. The modest incremental cost of adding additional cancer genes to high-throughput sequencing-based panels has made the development of drugs targeting increasingly smaller subsets of molecularly defined patients with cancer financially and logistically feasible6. The development of inhibitors effective in cancers driven by rare genomic mutations has required the concurrent development of clinical trial designs, such as basket trials, in which eligibility is  \nbased on mutational status instead of organ site, cancer stage and histology7. With the advent of basket studies, many oncologistsnow consider that tumor genomic profiling should be offered to all patients with cancer who are not candidates for curative-intent local or systemic therapy8.  \nAt present, several standalone testsora panel are typically used to capture a set of genomic, transcriptomic or epigenomic features in a tumor to inform patient treatment9. However, falling costs are making whole-genome sequencing (WGS) a potentially attractive proposition as a single all-encompassing test to identify cancer drivers and other genomic features, which may not be captured by standard testing but are clinically actionable10. This approach is being explored in the UK by the 100,000 Genomes Project (100kGP), which is seeking to deliver the  \n1Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. 2University College London Cancer Institute, University College London, London, UK. 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 4Broad Institute of MIT and Harvard, Cambridge, MA, USA. 5Harvard Medical School, Boston, MA, USA. 6Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK. 7Systems Biology & Biomedical Data Science Laboratory, University of Konstanz, Konstanz, Germany. 8Division of Molecular Pathology, The Institute of Cancer Research, London, UK. 9Division of Cancer Therapeutics, The Institute of Cancer Research","cbCaibdW7D5X43IV","https://ap.wps.com/l/cbCaibdW7D5X43IV","pdf",5985172,25,"English","# Study design and dataset\n## Patient cohort and sequencing\n## Driver gene identification\n# Clinical relevance and actionable targets\n## Clinically informative mutational signatures\n## FDA therapies and clinical trials","[{\"question\":\"What dataset and sequencing approach were used in the study?\",\"answer\":\"The analysis used whole-genome sequencing of 10,478 tumor-normal genomes from patients spanning 35 cancer types recruited to the UK 100,000 Genomes Project.\"},{\"question\":\"How many candidate driver genes were identified, and were any newly discovered?\",\"answer\":\"The study identified 330 candidate driver genes, including 74 that were not previously known to be associated with any cancer.\"},{\"question\":\"How does the study connect genomic findings to precision oncology?\",\"answer\":\"It estimates that about 55% of patients harbor clinically relevant mutations that predict sensitivity or resistance to certain treatments or eligibility for clinical trials, and it uses chemogenomic analysis to propose additional druggable targets.\"}]","Analysis of 10,478 Cancer Genomes Identifies Candidate Driver Genes and Opportunities for Precision Oncology | PDF",1790022205,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/932b7fd5423194fce683a911b16859a1.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1441a65cb035277eb1fa3a7f318ee2a5.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce1f6397bd41a8f52dec2d8ebae25dae.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea9c19544ce23764dfe0974ab31e8f04.webp",980,1301]